Update – Kalziumstoffwechsel

Abstract

A finely balanced control system keeps the extracellular calcium concentration within narrow limits. Disorders of calcium metabolism are often based on altered parathormone levels. Symptoms are not always clear, sometimes they are even missing: the more it is important to know possible associated diseases. The author presents basics, current diagnostics and concrete therapy options. Central hormone for the regulation of the calcium balance is the parathyroid hormone. With decreasing calcium, PTH leads to an increase in extracellular free calcium concentration in three ways. The classic symptoms of pHPT (polyuria, polydipsia, “stone, leg, and stomach pain”) are rare now, as the condition is diagnosed much earlier. Treatment of choice in all symptomatic patients with pHPT is surgery. FHH and pHPT are both characterized by hypercalcaemia and increased parathyroid hormone. The differential diagnosis of urinary calcium excretion, which is usually lower in FHH but normal or elevated in pHPT, is crucial. In primary hypoparathyroidism, parathyroid failure interferes with calcium homeostasis at a central location. Consequences are hypocalcaemia, hyperphosphatemia and lack of active vitamin D. Due to increased urinary calcium excretion, patients with ADH are at high risk for kidney stones, nephrocalcinosis and the development of renal insufficiency. Recently, rhPTH 1-84 has been available for the treatment of hypoparathyroidism. However, long-term data is still lacking to provide a safe indication, considering potential effects and side effects.

Ein fein austariertes Regelsystem hält die extrazelluläre Kalziumkonzentration in engen Grenzen. Bei Störungen des Kalziumstoffwechsels liegen oft veränderte Parathormonspiegel vor. Nicht immer sind die Symptome eindeutig, manchmal fehlen sie sogar: Umso wichtiger ist es, mögliche assoziierte Erkrankungen zu (er)kennen. Der Autor stellt Grundlagen, aktuelle Diagnostik und konkrete Therapieoptionen vor.

Schlüsselwörter

hormonelles Regelsystem - Kalziumkonzentration - CaSR - FHH - rhPTH1-84

Key words

hormonal control system - calcium concentration - CaSR - FHH - rhPTH1-84

• Literatur

• 1 Jakob F. Kalziumbilanz und systemische Regulationsprinzipien. In: Blum H, Müller-Wieland D. Hrsg. Klinische Pathophysiologie. 10., vollständig überarbeitete und erweiterte Auflage. Stuttgart: Thieme; 2018.
• 2 Hannan FM, Kallay E, Chang W. et al. The Calcium-sensing receptor in physiology and in calcitropic and noncalcitropic diseases. Nat Rev Endocrinol 2018; 15: 33-51
• 3 Bilezikian JP, Bandeira L, Khan A. et al. Hyperparathyroidism. Lancet 2018; 39: 168-178 . doi:10.1016/S0140-6736(17)31430-7
• 4 Insogna KL. Primary Hyperparathyroidism. N Engl J Med 2018; 379: 1050-1059
• 5 Castellano E, Attanasio R, Boriano A. et al. Sex Difference in the Clinical Presentation of Primary Hyperparathyroidism: Influence of Menopausal Status. J Clin Endocrinol Metab 2017; 102: 4148-4152
• 6 Mayr B, Schnabel D, Dörr HG. et al. Genetics in Endocrinology: Gain and loss of function mutations of the calcium-sensing receptor and associated proteins: current treatment concepts. Eur J Endocrinol 2016; 174: R189-R208
• 7 Bilezikian JP, Brandi ML, Eastell R. et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab 2014; 99: 3561-3569
• 8 Wilhelm SM, Wang TS, Ruan DT. et al. The American Association of Endocrine Surgeons Guidelines for Definitive Management of Primary Hyperparathyroidism. JAMA Surg 2016; 151: 959-968
• 9 Marcocci C, Bollerslev J, Khan AA. et al. Medical management of primary hyperparathyroidism: proceedings of the fourth International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism. J Clin Endocrinol Metab 2014; 99: 3607-3618
• 10 Peacock M, Bolognese MA, Borofsky M. et al. Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study. J Clin Endocrinol Metab 2009; 94: 4860-4867
• 11 Camozzi V, Luisetto G, Basso SM. et al. Treatment of chronic hypercalcemia. Med Chem 2012; 8: 556-563
• 12 Tsvetov G, Hirsch D, Shimon I. et al. Thiazide Treatment in Primary Hyperparathyroidism-A New Indication for an Old Medication?. J Clin Endocrinol Metab 2017; 102: 1270-1276
• 13 Hinnie J, Bell E, McKillop E. et al. The prevalence of familial hypocalciuric hypercalcemia. Calcif Tissue Int 2001; 68: 216-218
• 14 Christensen SE, Nissen PH, Vestergaard P. et al. Discriminative power of three indices of renal Calcium excretion for the distinction between familial hypocalciuric hypercalcaemia and primary hyperparathyroidism: a follow-up study on methods. Clin Endocrinol 2008; 69: 713-720
• 15 Szczawinska D, Schnabel D, Letz S. et al. A homozygous CaSR mutation causing a FHH phenotype completely masked by vitamin D deficiency presenting as rickets. J Clin Endocrinol Metab 2014; 99: E1146-E1153
• 16 Gafni RI, Collins MT. Hypoparathyroidism. N Engl J Med 2019; 380: 1738-1747
• 17 Bollerslev J, Rejnmark L, Marcocci C. et al. European Society of Endocrinology Clinical Guideline: Treatment of chronic hypoparathyroidism in adults. Eur J Endocrinol 2015; 173: G1-G20
• 18 Mannstadt M, Clarke BL, Vokes T. et al. Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study. Lancet Diabetes Endocrinol 2013; 1: 275-283
• 19 Rubin MR, Cusano NE, Fan WW. et al. Therapy of Hypoparathyroidism With PTH(1-84): A Prospective Six Year Investigation of Efficacy and Safety. J Clin Endocrinol Metab 2016; 101: 2742-2750